Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NovaBay Pharmaceuticals (NBY) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to 1.13%.

  • NovaBay Pharmaceuticals' Return on Capital Employed rose 21000.0% to 1.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.13%, marking a year-over-year increase of 21000.0%. This contributed to the annual value of 1.72% for FY2024, which is 12400.0% down from last year.
  • NovaBay Pharmaceuticals' Return on Capital Employed amounted to 1.13% in Q3 2025, which was up 21000.0% from 6.72% recorded in Q4 2024.
  • NovaBay Pharmaceuticals' 5-year Return on Capital Employed high stood at 0.45% for Q3 2022, and its period low was 6.72% during Q4 2024.
  • For the 5-year period, NovaBay Pharmaceuticals' Return on Capital Employed averaged around 1.59%, with its median value being 0.95% (2022).
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -61000bps in 2024, then soared by 21000bps in 2025.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Return on Capital Employed stood at 0.6% in 2021, then plummeted by -58bps to 0.95% in 2022, then skyrocketed by 35bps to 0.62% in 2023, then plummeted by -991bps to 6.72% in 2024, then surged by 83bps to 1.13% in 2025.
  • Its Return on Capital Employed stands at 1.13% for Q3 2025, versus 6.72% for Q4 2024 and 3.23% for Q3 2024.